Edesa Biotech, Inc. (EDSA)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 09-30. Amounts in USD.

Revenue TTM

0 500K 1M 1.5M Q4 '15: 758.7K Q1 '16: 1M Q2 '16: 1.2M Q3 '16: 1.2M Q4 '16: 1.3M Q1 '17: 925.4K Q2 '17: 662.1K Q3 '17: 501.5K Q4 '17: 228.3K Q1 '18: 106.9K Q2 '18: 108K Q3 '18: 87.4K Q4 '18: 138.8K Q1 '19: 118.3K Q2 '19: 54.3K Q3 '19: 54.8K Q4 '19: 410.9K Q1 '20: 518.7K Q2 '20: 629.2K Q3 '20: 738.7K Q4 '20: 328.8K Q1 '21: 221K Q2 '21: 110.5K Q3 '21: 500 Q4 '21: 0 Q4 '15 Q4 '16 Q4 '17 Q4 '18 Q4 '19 Q4 '20 Q4 '21

Gross Profit TTM

-150K 0 150K 300K 450K Q4 '20: 311.2K Q1 '21: 207.2K Q2 '21: 106.7K Q3 '21: -1.8K Q4 '21: 0 Q4 '20 Q1 '21 Q2 '21 Q3 '21 Q4 '21

Revenue minus cost of sales. This filer tags no gross profit of its own..

Operating Income TTM

-27M -18M -9M 0 9M 18M 27M Q4 '16: -4.9M Q1 '17: -5M Q2 '17: -5.1M Q3 '17: -5.2M Q4 '17: -5.2M Q1 '18: -5.2M Q2 '18: -5.4M Q3 '18: -4.5M Q4 '18: -4.3M Q1 '19: -3.4M Q2 '19: -2.6M Q3 '19: -3.5M Q4 '19: -3.2M Q1 '20: -3.9M Q2 '20: -4.9M Q3 '20: -5.4M Q4 '20: -6.4M Q1 '21: -7.9M Q2 '21: -15.9M Q3 '21: -20.2M Q4 '21: -23.7M Q1 '22: -26.2M Q2 '22: -21.3M Q3 '22: -21M Q4 '22: -18.4M Q1 '23: -15.6M Q2 '23: -13.4M Q3 '23: -9.7M Q4 '23: -9.2M Q1 '24: -8.7M Q2 '24: -8.5M Q3 '24: -8.4M Q4 '24: -7M Q1 '25: -7.1M Q2 '25: -6.5M Q3 '25: -6.4M Q4 '25: -7.9M Q1 '26: -8.4M Q2 '26: -11M Q3 '26: -14.6M Q4 '17 Q1 '19 Q2 '20 Q3 '21 Q4 '22 Q1 '24 Q2 '25 Q3 '26

Net Income TTM

-21M -14M -7M 0 7M 14M 21M Q4 '16: -5M Q1 '17: -4.9M Q2 '17: -5.1M Q3 '17: -5.2M Q4 '17: -5M Q1 '18: -4.9M Q2 '18: -5.2M Q3 '18: -4.4M Q4 '18: -3.5M Q1 '19: -2.5M Q2 '19: -1.7M Q3 '19: -2.5M Q4 '19: -3.1M Q1 '20: -3.9M Q2 '20: -4.8M Q3 '20: -5.3M Q4 '20: -6.4M Q1 '21: -7.9M Q2 '21: -8.7M Q3 '21: -11.7M Q4 '21: -13.3M Q1 '22: -15.1M Q2 '22: -17.4M Q3 '22: -18.4M Q4 '22: -17.5M Q1 '23: -15.5M Q2 '23: -13.3M Q3 '23: -9.5M Q4 '23: -8.4M Q1 '24: -7.7M Q2 '24: -7.2M Q3 '24: -6.9M Q4 '24: -6.2M Q1 '25: -6.1M Q2 '25: -5.8M Q3 '25: -5.9M Q4 '25: -7.2M Q1 '26: -7.8M Q2 '26: -10.4M Q3 '26: -14.1M Q4 '17 Q1 '19 Q2 '20 Q3 '21 Q4 '22 Q1 '24 Q2 '25 Q3 '26

Cost of Revenue TTM

0 300K 600K 900K Q4 '15: 580.8K Q1 '16: 797K Q2 '16: 822.7K Q3 '16: 710.7K Q4 '16: 818.6K Q1 '17: 585.1K Q2 '17: 387.6K Q3 '17: 345.2K Q4 '17: 250K Q1 '18: 174.3K Q2 '18: 168.5K Q3 '18: 136.5K Q4 '18: 133.3K Q1 '19: 130.5K Q2 '19: 64.9K Q3 '19: 19.3K Q4 '20: 17.6K Q1 '21: 13.8K Q2 '21: 3.8K Q3 '21: 2.3K Q4 '21: 0 Q2 '16 Q1 '17 Q4 '17 Q3 '18 Q2 '19 Q1 '21 Q4 '21

Operating Cash Flow TTM

-18M -12M -6M 0 6M 12M 18M Q4 '16: -4.5M Q1 '17: -4.7M Q2 '17: -4.9M Q3 '17: -4.8M Q4 '17: -4.7M Q1 '18: -4.5M Q2 '18: -4.6M Q3 '18: -4.8M Q4 '18: -4.6M Q1 '19: -3.9M Q2 '19: -2.9M Q3 '19: -4.9M Q4 '19: -5.2M Q1 '20: -5.6M Q2 '20: -6.4M Q3 '20: -4.6M Q4 '20: -5M Q1 '21: -7.2M Q2 '21: -13.2M Q3 '21: -15M Q4 '21: -13.7M Q1 '22: -13.9M Q2 '22: -7.1M Q3 '22: -7M Q4 '22: -12.3M Q1 '23: -10.9M Q2 '23: -12M Q3 '23: -10.8M Q4 '23: -6.6M Q1 '24: -6.3M Q2 '24: -6.3M Q3 '24: -5.4M Q4 '24: -4.9M Q1 '25: -5M Q2 '25: -5.7M Q3 '25: -6.6M Q4 '25: -7.3M Q1 '26: -7.9M Q2 '26: -7.5M Q3 '26: -8.9M Q4 '17 Q1 '19 Q2 '20 Q3 '21 Q4 '22 Q1 '24 Q2 '25 Q3 '26

Free Cash Flow TTM

-18M -12M -6M 0 6M 12M 18M Q4 '15: -4.7M Q1 '16: -4.7M Q2 '16: -4.6M Q3 '16: -4.6M Q4 '16: -4.9M Q1 '17: -5M Q2 '17: -5.2M Q3 '17: -5.1M Q4 '17: -5M Q1 '18: -4.7M Q2 '18: -5M Q3 '18: -5.2M Q4 '18: -5M Q1 '19: -4.2M Q2 '19: -3M Q3 '19: -4.9M Q4 '19: -5.2M Q1 '20: -5.6M Q2 '20: -6.4M Q3 '20: -4.6M Q4 '20: -5M Q1 '21: -7.2M Q2 '21: -13.2M Q3 '21: -15M Q4 '22: -12.3M Q1 '23: -10.9M Q2 '23: -12M Q3 '23: -10.8M Q4 '23: -6.6M Q4 '15 Q4 '16 Q4 '17 Q4 '18 Q4 '19 Q4 '20 Q4 '22 Q4 '23

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 30M 60M 90M Q1 '14: 74M Q2 '14: 76.2M Q3 '14: 86.9M Q1 '15: 79.5M Q2 '15: 79.5M Q3 '15: 8.5M Q3 '16: 8.4M Q3 '23: 2.9M Q1 '24: 3.1M Q2 '24: 3.2M Q3 '24: 3.2M Q1 '25: 3.3M Q2 '25: 5.3M Q3 '25: 7M Q1 '26: 8M Q2 '26: 8.5M Q3 '26: 9M Q2 '14 Q2 '15 Q3 '23 Q3 '24 Q3 '25 Q3 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-4.50 -3.00 -1.50 0.00 1.50 3.00 4.50 Q4 '15: -0.18 Q1 '16: -0.35 Q2 '16: -0.44 Q3 '16: -0.63 Q4 '16: -0.56 Q1 '17: -0.52 Q2 '17: -1.18 Q3 '17: -1.88 Q4 '17: -2.56 Q1 '18: -3.34 Q2 '18: -3.48 Q3 '18: -2.77 Q4 '18: -2.06 Q1 '19: -1.24 Q2 '19: -0.50 Q3 '19: -0.67 Q4 '19: -0.64 Q1 '20: -0.68 Q2 '20: -0.69 Q3 '20: -0.59 Q4 '20: -0.74 Q1 '21: -0.85 Q2 '21: -0.87 Q3 '21: -1.03 Q4 '21: -1.08 Q1 '22: -1.15 Q2 '24: -2.36 Q3 '24: -2.20 Q4 '24: -1.93 Q1 '25: -1.87 Q2 '25: -1.59 Q3 '25: -1.32 Q4 '25: -1.35 Q1 '26: -1.15 Q2 '26: -1.34 Q3 '26: -1.69 Q4 '15 Q1 '17 Q2 '18 Q3 '19 Q4 '20 Q1 '22 Q2 '25 Q3 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.